Acute lymphoblastic leukemia
Conditions
Interventions
Acute lymphoblastic leukemia children under 18 years of age treated with belimumab:None
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: 1.Age between 28 days and 18 years, with no gender restrictions; 2.Refractory response to initial chemotherapy, characterized by an inability to continue due to severe complications during the standard induction remission protocol or consolidation therapy, or a suboptimal response to chemotherapy, indicated by minimal residual disease (MRD) levels of >=0.01% as determined by flow cytometry, PCR, or next-generation sequencing after two standard induction cycles; 3.Progression to the maintenance phase or bridge transplantation; 4.Relapsed B-cell acute lymphoblastic leukemia (B-ALL), defined by>=5% bone marrow involvement post-complete remission or extramedullary relapse; 5.Recurrence of MRD, indicated by MRD levels of =0.01% reoccurring after achieving <0.01% on standard treatment.
Exclusion criteria
Exclusion criteria: 1.Pediatric patients presenting with extramedullary recurrence confined solely to the central nervous system; 2.Individuals who did not undergo bone marrow evaluation both prior to and following belimumab therapy; 3.Patients who failed to complete the prescribed course of treatment due to various reasons; 4.Patients who did not undergo assessments for cytokines, liver function, and other relevant tests during the course of belimumab treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reaction; | — |
Countries
China
Contacts
Public ContactTu Yingqiu
The First Affiliated Hospital of Nanchang University
Outcome results
None listed